Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Reduction of mortality, cardiac damage, and cerebral damage by IL-1 inhibition in a murine model of TTP

Romain Muller, Raphaël Cauchois, Marie Lagarde, Sandrine Roffino, Cécile Genovesio, Samantha Fernandez, Guillaume Hache, Benjamin Guillet, Yéter Kara, Marion Marlinge, Peter Lenting, Pascale Poullin, Françoise Dignat-George, Edwige Tellier, Gilles Kaplanski

Blood (2024) 143 (26): 2791–2803.

https://doi.org/10.1182/blood.2023021974

Published: 2024

Includes: Supplemental data

Journal Articles

Ineffective Erythropoiesis Negatively Impacts the Erythroblastic Island in Sickle Cell Disease

Auria Godard, Julien Grenier, Jonatane Andrieu, Sophie Beley, Pascale Poullin, Sandra Manceau, Laure Joseph, Maria De Grandis, Wassim El Nemer

Blood (2023) 142 (Supplement 1): 15.

https://doi.org/10.1182/blood-2023-181647

Published: 2023

Journal Articles

Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination

Adrien Picod, Jean-Michel Rebibou, Antoine Dossier, Bérengère Cador, David Ribes, Claire Vasco-Moynet, Caroline Stephan, Mathieu Bellal, Alain Wynckel, Pascale Poullin, Edwige Péju, Laure Ricard, Jean-Emmanuel Kahn, Raïda Bouzid, Ygal Benhamou, Bérangère Joly, Agnès Veyradier, Paul Coppo

Blood (2022) 139 (16): 2565–2569.

https://doi.org/10.1182/blood.2021015149

Published: 2022

Journal Articles

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Blood (2021) 137 (6): 733–742.

https://doi.org/10.1182/blood.2020008021

Published: 2021

Includes: Supplemental data

Journal Articles

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Blood (2019) 134 (24): 2209–2217.

https://doi.org/10.1182/blood.2019000748

Published: 2019

Includes: Supplemental data

Journal Articles

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura

Blood (2018) 132 (20): 2143–2153.

https://doi.org/10.1182/blood-2018-04-840090

Published: 2018

Includes: Supplemental data

Journal Articles

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

Miguel Hie, Julie Gay, Lionel Galicier, François Provôt, Claire Presne, Pascale Poullin, Guy Bonmarchand, Alain Wynckel, Ygal Benhamou, Philippe Vanhille, Aude Servais, Dominique Bordessoule, Jean-Philippe Coindre, Mohamed Hamidou, Jean-Paul Vernant, Agnès Veyradier, Paul Coppo, the French Thrombotic Microangiopathies Reference Centre

Blood (2014) 124 (2): 204–210.

https://doi.org/10.1182/blood-2014-01-550244

Published: 2014

Includes: Supplemental data

Journal Articles

Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center

Miguel HIE, MD, Julie Gay, MD, Lionel Galicier, MD, Francois Provot, Sandrine Malot, Pascale Poullin, MD, Guy Bonmarchand, MD, Alain Wynckel, MD, Ygal Benhamou, MD, Philippe Vanhille, Dominique Bordessoule, MD, PhD, Jean-Paul Vernant, Agnes Veyradier, MD PhD, Paul Coppo, MD PhD

Blood (2013) 122 (21): 448.

https://doi.org/10.1182/blood.V122.21.448.448

Published: 2013

Journal Articles

HLA-DRB1*11: a Strong Risk Factor for Acquired Severe ADAMTS13 Deficiency-Related Idiopathic Thrombotic Thrombocytopenic Purpura in Caucasians.

Paul Coppo, Virginia Lepage, Marc Busson, Agnes Veyradier, Karine Clabault, Alain Wynckel, Pascale Poullin, Sandrine Malot, Elie Azoulay, Lionel Galicier, Marc Buffet, Dominique Bordessoule, Jean-Paul Mira, Eric Rondeau, Dominique Charron, MD, PhD, Pascale Loiseau

Blood (2009) 114 (22): 2412.

https://doi.org/10.1182/blood.V114.22.2412.2412

Published: 2009

Journal Articles

First-Line Rituximab Efficacy and Safety in Patients with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Experiencing a Non Optimal Response to Therapeutical Plasma Exchange: Results of a Prospective Multicenter Phase 2 Study From the French Reference Center for the Management of Thrombotic Microangiopathies.

Blood (2009) 114 (22): 890.

https://doi.org/10.1182/blood.V114.22.890.890

Published: 2009

Journal Articles

Idiopathic Thrombotic Microangiopathies: Antinuclear Antibodies, Platelet Count and Creatinin Level Can Predict a Severe ADAMTS13 Deficiency.

Paul Coppo, MD, PhD, Alain Wynckel, MD, Karine Clabault, MD, Mickael Schwarzinger, MD, Matthieu Monge, MD, Pascale Poullin, MD, Elie Azoulay, MD, PhD, Lionel Galicier, MD, Jean-Paul Mira, MD, PhD, Dominique Bordessoule, MD, Norbert C. Gorin, MD, Jean-Paul Vernant, MD, Agnès Veyradier

Blood (2007) 110 (11): 3923.

https://doi.org/10.1182/blood.V110.11.3923.3923

Published: 2007

Journal Articles

Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity

Blood (2006) 109 (7): 2815–2822.

https://doi.org/10.1182/blood-2006-02-006064

Published: 2006

Journal Articles

Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases

Fadi Fakhouri, Jean-Paul Vernant, Agnès Veyradier, Martine Wolf, Gilles Kaplanski, Raynald Binaut, Manfred Rieger, Friedrich Scheiflinger, Pascale Poullin, Benjamin Deroure, Richard Delarue, Philippe Lesavre, Philippe Vanhille, Olivier Hermine, Giuseppe Remuzzi, Jean-Pierre Grünfeld

Blood (2005) 106 (6): 1932–1937.

https://doi.org/10.1182/blood-2005-03-0848

Published: 2005

NARROW

Reduction of mortality, cardiac damage, and cerebral damage by IL-1 inhibition in a murine model of TTP

Ineffective Erythropoiesis Negatively Impacts the Erythroblastic Island in Sickle Cell Disease

Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center

HLA-DRB1*11: a Strong Risk Factor for Acquired Severe ADAMTS13 Deficiency-Related Idiopathic Thrombotic Thrombocytopenic Purpura in Caucasians.

Idiopathic Thrombotic Microangiopathies: Antinuclear Antibodies, Platelet Count and Creatinin Level Can Predict a Severe ADAMTS13 Deficiency.

Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity

Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only